TRIAL PHASE STATUS PATIENT PROFILE COUNTRIES PUBLICATIONS TMC125-C207 IIa Completed HIV-1 infected subjects with NNRTI resistance France, Germany, UK Manuscript in AIDS TMC125-C208 IIa Completed ARV* treatment-naïve HIV-1 infected subjects Russia Manuscript in AIDS TMC125-C203 IIb Completed 3-class experienced HIV-1 infected subjects failing ART** Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Poland, Portugal, Spain, Switzerland, UK TMC125-C209 IIb Completed 3-class experienced HIV-1 infected subjects failing ART** Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Poland, Portugal, Spain, Switzerland, UK TMC125-C211 II Completed HIV-1 infected subjects who were randomized in any sponsor-selected TMC125 trial to an active control arm and either virologically failed or completed the entire treatment period, or to placebo arm and were treated for at least 48 weeks Argentina, Belgium, Brazil, Canada, Switzerland, Germany, Spain, France, Great Britain, Italy, Mexico, The Netherlands, Poland, Portugal, Russia, Thailand, USA, South Africa TMC125-C213 II Recruiting Antiretroviral Experienced HIV-1 Infected Children and Adolescents Argentina, Belgium, Brazil, Canada, Germany, Spain, France, Great Britain, Italy, The Netherlands, Puerto Rico, Portugal, Romania, USA TMC125-C223 IIb Completed HIV-1 infected subjects with NNRTI resistance and at least 3 primary PI mutations USA Manuscript in AIDS TMC125-C227 II Completed HIV-1 infected subjects who are PI-naïve and failing on a first-line NNRTI-containing therapy Argentina, Brazil, Spain, Great Britain, Mexico, Russia, Thailand, South Africa Manuscript in HIV Med TMC125-C229 II Completed HIV-1 infected subjects who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks Belgium, Canada, Switzerland, Germany, Spain, France, Great Britain, Italy, The Netherlands, Poland, Portugal, USA TMC125-TiDP2-C238 II Recruiting Treatment experienced HIV-1 infected patients France, USA TMC125-C206 (DUET 1) III Completed HIV-1 infected patients with limited to no treatment options USA, South Africa, Thailand, Argentina, Brazil, Chile and Mexico DUET 1 manuscript in the Lancet TMC125-C216 (DUET 2) III Completed HIV-1 infected patients with limited to no treatment options Australia, Belgium, Canada, France, Germany, Italy, The Netherlands, Poland, Portugal, Spain, UK and USA DUET 2 manuscript in the Lancet TMC125-C217 III Completed HIV-1 infected patients who participated in one of the DUET trials Argentina, Australia, Belgium, Brazil, Canada, Chile, Costa Rica, France, Germany, Italy, Mexico, The Netherlands, Panama, Poland, Portugal, Puerto Rico, South Africa, Spain, Thailand, UK and USA TMC125-TiDP35-C239 III Not yet recruiting Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents Argentina, Spain, France, Great Britain, Italy, Puerto Rico, Portugal, USA TMC125-C214 EAP Recruiting HIV-1 infected patients who have failed multiple antiretroviral regimens Argentina, Belgium, Brazil, Canada, Chile, Colombia, Cyprus, Germany, Denmark, Spain, Greece, Guatemala, Italy, Jamaica, Luxembourg, Mexico, Malta, Netherlands, Peru, Puerto Rico, Russia, El Salvador, Switzerland, Sweden, Thailand, Turkey, Taiwan, Uruguay, USA, Venezuela

ARV* = antiretroviral

ART** = antiretroviral therapy